CytoDyn (OTC: CYDY) Announces Webcast for its Annual Meeting of Stockholders
VANCOUVER, Washington, Sep 06, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that […]